Science drives innovation
With the increasing pipeline of novel targeted and IO agents emerging from company pipelines these days, one key question which often comes up is can we get rid of chemotherapy – even in the first line setting?
On the upside, many patients would likely prefer to avoid chemotherapy treatment where at all possible, but on the downside, most of these agents are now available cheaply as generics and switching in another therapy doesn’t mean the absence of any additional side effects, just different ones.
During the 2022–2023 time frame we are going to see a surge in IO-IO readouts from both phase 2 and 3 trials as the data begin to mature over time.
In our latest look at IO combination strategies, we take a look at one such approach and examine the pros and cons involved based on the data available…
BSB subscribers can read up on our ongoing oncology commentary and analysis – you can either log-in or click to access the back story behind the latest innovation.
This content is restricted to subscribers